CHAI and LATAIE

New genetic diseases of CTLA-4 checkpoint insufficiency

Bernice Lo, Jill M. Fritz, Helen C. Su, Gulbu Uzel, Michael B. Jordan, Michael J. Lenardo

Research output: Contribution to journalArticle

39 Citations (Scopus)

Abstract

CTLA-4 is a critical inhibitory 'checkpoint' molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ultimately the consequence of treatmentinduced CTLA-4 deficiency. Here, we review these 2 diseases and CTLA-4 blockade therapy, emphasizing the crucial role of CTLA-4 in immune checkpoint regulation.

Original languageEnglish
Pages (from-to)1037-1042
Number of pages6
JournalBlood
Volume128
Issue number8
DOIs
Publication statusPublished - 25 Aug 2016
Externally publishedYes

Fingerprint

Inborn Genetic Diseases
Immunotherapy
Chemical activation
Neoplasms
Molecules
Therapeutics

ASJC Scopus subject areas

  • Immunology
  • Biochemistry
  • Hematology
  • Cell Biology

Cite this

Lo, B., Fritz, J. M., Su, H. C., Uzel, G., Jordan, M. B., & Lenardo, M. J. (2016). CHAI and LATAIE: New genetic diseases of CTLA-4 checkpoint insufficiency. Blood, 128(8), 1037-1042. https://doi.org/10.1182/blood-2016-04-712612

CHAI and LATAIE : New genetic diseases of CTLA-4 checkpoint insufficiency. / Lo, Bernice; Fritz, Jill M.; Su, Helen C.; Uzel, Gulbu; Jordan, Michael B.; Lenardo, Michael J.

In: Blood, Vol. 128, No. 8, 25.08.2016, p. 1037-1042.

Research output: Contribution to journalArticle

Lo, B, Fritz, JM, Su, HC, Uzel, G, Jordan, MB & Lenardo, MJ 2016, 'CHAI and LATAIE: New genetic diseases of CTLA-4 checkpoint insufficiency', Blood, vol. 128, no. 8, pp. 1037-1042. https://doi.org/10.1182/blood-2016-04-712612
Lo B, Fritz JM, Su HC, Uzel G, Jordan MB, Lenardo MJ. CHAI and LATAIE: New genetic diseases of CTLA-4 checkpoint insufficiency. Blood. 2016 Aug 25;128(8):1037-1042. https://doi.org/10.1182/blood-2016-04-712612
Lo, Bernice ; Fritz, Jill M. ; Su, Helen C. ; Uzel, Gulbu ; Jordan, Michael B. ; Lenardo, Michael J. / CHAI and LATAIE : New genetic diseases of CTLA-4 checkpoint insufficiency. In: Blood. 2016 ; Vol. 128, No. 8. pp. 1037-1042.
@article{46922b324b2a4f73b82e470addb0c55b,
title = "CHAI and LATAIE: New genetic diseases of CTLA-4 checkpoint insufficiency",
abstract = "CTLA-4 is a critical inhibitory 'checkpoint' molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ultimately the consequence of treatmentinduced CTLA-4 deficiency. Here, we review these 2 diseases and CTLA-4 blockade therapy, emphasizing the crucial role of CTLA-4 in immune checkpoint regulation.",
author = "Bernice Lo and Fritz, {Jill M.} and Su, {Helen C.} and Gulbu Uzel and Jordan, {Michael B.} and Lenardo, {Michael J.}",
year = "2016",
month = "8",
day = "25",
doi = "10.1182/blood-2016-04-712612",
language = "English",
volume = "128",
pages = "1037--1042",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - CHAI and LATAIE

T2 - New genetic diseases of CTLA-4 checkpoint insufficiency

AU - Lo, Bernice

AU - Fritz, Jill M.

AU - Su, Helen C.

AU - Uzel, Gulbu

AU - Jordan, Michael B.

AU - Lenardo, Michael J.

PY - 2016/8/25

Y1 - 2016/8/25

N2 - CTLA-4 is a critical inhibitory 'checkpoint' molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ultimately the consequence of treatmentinduced CTLA-4 deficiency. Here, we review these 2 diseases and CTLA-4 blockade therapy, emphasizing the crucial role of CTLA-4 in immune checkpoint regulation.

AB - CTLA-4 is a critical inhibitory 'checkpoint' molecule of immune activation. Several recent reports have described patients with immune dysregulation and lymphoproliferative disease resulting from 2 different genetic diseases that directly or indirectly cause CTLA-4 deficiency. Numerous articles have also been published describing CTLA-4 blockade in cancer immunotherapy and its side effects, which are ultimately the consequence of treatmentinduced CTLA-4 deficiency. Here, we review these 2 diseases and CTLA-4 blockade therapy, emphasizing the crucial role of CTLA-4 in immune checkpoint regulation.

UR - http://www.scopus.com/inward/record.url?scp=84984801447&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984801447&partnerID=8YFLogxK

U2 - 10.1182/blood-2016-04-712612

DO - 10.1182/blood-2016-04-712612

M3 - Article

VL - 128

SP - 1037

EP - 1042

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -